Difference in willingness-to-pay for prostate cancer screening between ill-informed and well-informed men: A contingent valuation survey

Urology

Volumn 77, Issue 6, 2011, Pages 1325-1329

  Yasunaga, Hideo ^a,b,c   Sugihara, Toru ^a,b,c   Imamura, Tomoaki ^a,b,c  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER SCREENING; CONTINGENT VALUATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; QUESTIONNAIRE;

AGED; ATTITUDE TO HEALTH; EARLY DETECTION OF CANCER; ECONOMICS, MEDICAL; FALSE POSITIVE REACTIONS; HEALTH CARE COSTS; HUMANS; INTERNET; JAPAN; MALE; MIDDLE AGED; PATIENT EDUCATION AS TOPIC; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; QUESTIONNAIRES; REGRESSION ANALYSIS;

EID: 79957910442     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2011.02.025     Document Type: Article

References (20)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics. CA Cancer J Clin. 2008;58:71-96.
2. Cancer Research UK. Prostate Cancer Statistics. London: Cancer Research UK, 2002.
3. Foundation for Promotion of Cancer Research. Cancer Statistics in Japan 2009. Available from: www.ganjoho.ncc.go.jp/public/statistics/backnumber/2009- en.html. Accessed February 1, 2011.
4. Ito K. Prostate-specific antigen-based screening for prostate cancer: Evidence, controversies and future perspectives. Int J Urol. 2009; 16:458-464.
5. Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360:1320-1328.
6. Hugosson J, Carlsson S, Aus G, et al. Mortality results from the Göteborg randomised population-based prostate-cancer screening trial. Lancet Oncol. 2010;11:725-732.
7. Committee for Establishment of the Guidelines on Screening for Prostate Cancer; Japanese Urological Association. Updated Japanese Urological Association Guidelines on prostate-specific antigen-based screening for prostate cancer in 2010. Int J Urol. 2010; 17:830-838.
8. Klose T. The contingent evaluation method in health care. Health Policy. 1999;47:97-123. (Pubitemid 29241789)
9. Smith RD. Construction of the contingent valuation market in health care: a critical assessment. Health Econ. 2003;12:609-628. (Pubitemid 37038358)
10. Yasunaga H, Ide H, Imamura T, Ohe K. Benefit evaluation of mass screening for prostate cancer: willingness-to-pay measurement using contingent valuation. Urology. 2006;68:1046-1050. (Pubitemid 44755438)
11. Kakehi Y, Naito S, for the Japanese Urological Association. Complication rates of ultrasound-guided prostate biopsy: a nation-wide survey in Japan. Int J Urol. 2008;15:319-321. (Pubitemid 351490162)
12. Kakehi Y, Kimoto T, Shiraishi T, et al. Prospective evaluation of selection criteria for active surveillance in Japanese patients with stage T1cN0M0 prostate cancer. Jpn J Clin Oncol. 2008;38:122-128. (Pubitemid 351337956)
13. Turnbull BW. The empirical distribution with arbitrarily grouped, censored and truncated data. J Roy Stat Soc B Met. 1976;38:290-295.
14. Alberini A, Hunt A, Markandya A. Willingness to pay to reduce mortality risks: Evidence from a three-country contingent valuation study. Environ Resour Econ. 2006;33:251-264. (Pubitemid 43341210)
15. Cantor SB, Volk RJ, Cass AR, Gilani J, Spann SJ. Psychological benefits of prostate cancer screening: the role of reassurance. Health Expect. 2002;5:104-113. (Pubitemid 34591871)
16. Schwartz LM, Woloshin S, Fowler FJ Jr, et al. Enthusiasm for cancer screening in the United States. JAMA. 2004;291:71-78. (Pubitemid 38040537)
17. Ransohoff DF, McNaughton CM, Fowler FJ. Why is prostate cancer screening so common when the evidence is so uncertain? A system without negative feedback. Am J Med. 2002;113:663-667. (Pubitemid 36015803)
18. Gattellari M, Ward JE. Does evidence-based information about screening for prostate cancer enhance consumer decision-making? A randomised controlled trial. J Med Screen. 2003;10:27-39. (Pubitemid 36560965)
19. Finney-Rutten LJ, Meissner HI, Breen N, et al. Factors associated with men's use of prostate-specific antigen screening: evidence from Health Information National Trends Survey. Prev Med. 2005;57: 90-104.
20. Volk RJ, Hawley ST, Kneuper S, et al. Trials of decision aids for prostate cancer screening: a systematic review. Am J Prev Med. 2007;33:428-434.